Only about a quarter of patients who have myelodysplastic syndrome (MDS) experienced hematologic improvement with erythropoiesis-stimulating agents (ESAs). Patients with lower-risk myelodysplastic ...
Patients with MDS report more symptoms than physicians, indicating a communication gap in symptom assessment. Allogeneic hematopoietic stem cell transplantation is the only cure but is limited to ...
Dublin, Jan. 22, 2018 (GLOBE NEWSWIRE) -- The "Market Spotlight: Myelodysplastic Syndrome (MDS)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results